This thesis examines hypertensive diseases of pregnancy (HDP) and their prevention and management using labetalol, hydralazine, and nifedipine. HDP—gestational hypertension, preeclampsia, and eclampsia—affects maternal health worldwide and requires pharmaceutical treatments to manage blood pressure and prevent problems. Labetalol, which lowers blood pressure without damaging the fetus, is a leading treatment; hydralazine, a vasodilator, manages severe hypertension caused by preeclampsia, whereas nifedipine, a calcium blocker, may prevent HDP in high-risk mothers. Antenatal care, blood pressure monitoring, lifestyle changes, and low-dose aspirin in high-risk pregnancies lower preeclampsia incidence in addition to medicine. When severe, timely delivery reduces the chances of sustained high blood pressure throughout pregnancy. Pharmacological therapies for pregnant women must be balanced against their risks and benefits, requiring personalized treatment strategies and close monitoring for best results.